PDPN and neoplasm: As podoplanin is known to be expressed in normal tissue, including lymphatic vessels, kidney podocytes, mesothelium, and alveolar epithelium, the complete blockade of podoplanin–CLEC-2 binding by the co-administration of anti-PLAG3 and anti-PLAG4 mAbs possessing no ADCC/CDC activity would be preferable as anti-tumor agents with minimal side effects.